CHEMEDIMMUNE, INC.

Biotech · Private

Lipid nanoparticle-encapsulated interferon alpha 2 (IFN-α2) encoding mini-plasmid DNA therapeutic

Grants
$853K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of IG7 as an enhancer of anti-PD-1 cancer immunotherapy$202,500
Federal grantDepartment of Health and Human Services · Phase I · OPN neutralization monoclonal antibody 100G2 for human pancreatic cancer immunotherapy$329,610
Federal grantDepartment of Health and Human Services · Phase I · Development of IFNA2-LNP01 for tumor lung metastases immunotherapy$320,597
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1660ISOTHERAPEUTICS GROUP, LLC——
1661BIOMIMETIX JV LLC——
1662OGB5, INC.——
1663CHEMEDIMMUNE, INC.——
1664KXT BIO INC.——
1665CURTANA PHARMACEUTICALS INC——
1666Pathfinder Therapeutics, Inc.—$9.6M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.